Unaudited Financial Results for the Quarter and Half yearly ended on 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Omkar Pharmachem Ltd reported its H1 FY26 results on 14 November 2025. For Q2 FY26, the company earned a total income of Rs. 13.94 lakhs, entirely from 'Other Operating Income' with no revenue from core operations. Profit after tax for the quarter was Rs. 5.07 lakhs versus Rs. 8.85 lakhs in Q2 FY25, a drop of about 43%. For H1 FY26, total income was flat at Rs. 27.44 lakhs (vs Rs. 27.00 lakhs a year ago), but expenses rose to Rs. 17.06 lakhs from Rs. 13.26 lakhs, pushing PAT down to Rs. 7.74 lakhs from Rs. 13.74 lakhs. The auditor (Dipal R. Shah & Co.) issued an unmodified limited review report. On the balance sheet, other equity remains negative at Rs. 57.27 lakhs, though it improved slightly from Rs. 65.00 lakhs.
The company has zero revenue from operations and is relying on other operating income and investment returns, with PAT falling nearly 44% year-on-year for H1. Combined with negative reserves, this suggests weak business activity and limited earnings momentum, which is negative for shareholders.